![Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label ... Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label ...](https://www.thelancet.com/cms/attachment/3fdd6731-2603-4814-8039-9bb9fa5cf394/gr1.gif)
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label ...
![Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era - Rivas‐Delgado - 2019 - British Journal of Haematology - Wiley Online Library Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era - Rivas‐Delgado - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7172830b-ff39-4b13-ab85-e9ca0a2f2365/bjh15708-fig-0002-m.jpg)
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era - Rivas‐Delgado - 2019 - British Journal of Haematology - Wiley Online Library
![Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group - ScienceDirect Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168827820304700-gr2.jpg)
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group - ScienceDirect
![National patterns of filled prescriptions and third line treatment use for privately insured women with overactive bladder - Mayo Clinic National patterns of filled prescriptions and third line treatment use for privately insured women with overactive bladder - Mayo Clinic](https://www.mayoclinic.org/-/media/kcms/gbs/medical-professionals/images/2021/05/18/17/16/overactive-diagram-fig1-767x535.jpg)
National patterns of filled prescriptions and third line treatment use for privately insured women with overactive bladder - Mayo Clinic
Prospects in the management of patients with follicular lymphoma beyond first-line therapy | Haematologica
![JCM | Free Full-Text | Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients JCM | Free Full-Text | Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients](https://www.mdpi.com/jcm/jcm-09-00648/article_deploy/html/images/jcm-09-00648-g001.png)
JCM | Free Full-Text | Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies | PLOS ONE
![Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis | Future Oncology Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2019-0429/asset/images/medium/figure1.gif)
Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis | Future Oncology
Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice
![First-, second- and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database | Lung Cancer Management First-, second- and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database | Lung Cancer Management](https://www.futuremedicine.com/cms/10.2217/lmt.15.12/asset/images/medium/figure1.gif)
First-, second- and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database | Lung Cancer Management
![Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box - ScienceDirect Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0304419X20302067-gr1.jpg)
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box - ScienceDirect
![Third-Line Treatment for Metastatic Colorectal Cancer | LONSURF® (trifluridine and tipiracil) tablets Third-Line Treatment for Metastatic Colorectal Cancer | LONSURF® (trifluridine and tipiracil) tablets](https://www.lonsurfhcp.com/Content/img/mCRC/mcrc-patients-third-line-treatment.png)
Third-Line Treatment for Metastatic Colorectal Cancer | LONSURF® (trifluridine and tipiracil) tablets
![Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-022-00757-8/MediaObjects/41408_2022_757_Figa_HTML.png)
Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal
![Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study - The Lancet HIV Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study - The Lancet HIV](https://www.thelancet.com/cms/attachment/3fc97607-2c9a-466f-834d-a4ebfad48cf2/gr1.jpg)
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study - The Lancet HIV
![Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice - ScienceDirect Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1533002818304717-gr2.jpg)
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice - ScienceDirect
![Lay Summary of the ERN RARE-LIVER Position Paper: Second-line and Third-line Therapy for Autoimmune Hepatitis Lay Summary of the ERN RARE-LIVER Position Paper: Second-line and Third-line Therapy for Autoimmune Hepatitis](https://rare-liver.eu/media/treatment_decisions_for_autimmune_hepatitis_aih_.jpg)
Lay Summary of the ERN RARE-LIVER Position Paper: Second-line and Third-line Therapy for Autoimmune Hepatitis
Zimbabwe's national third-line antiretroviral therapy program: Cohort description and treatment outcomes | PLOS ONE
![The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New Options | Anticancer Research The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New Options | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/31/2/649/F1.large.jpg)